Nutrition Intervention for Pancreatic Cancer (NCT07554560) | Clinical Trial Compass
RecruitingNot Applicable
Nutrition Intervention for Pancreatic Cancer
United States18 participantsStarted 2026-04-07
Plain-language summary
Patients with pancreatic cancer (pancreatic ductal adenocarcinoma (PDAC) and pancreatic neuroendocrine tumor (NET)) commonly experience fat malabsorption due to exocrine pancreatic insufficiency (EPI) and leads to gastrointestinal (GI) symptoms, malnutrition, weight loss, and reduced quality of life (QoL). Current standard treatment, pancreatic enzyme replacement therapy (PERT), is limited by suboptimal adherence, high cost, and partial effectiveness to prevent fat malabsorption. The objective of the study is to assess the feasibility and maintenance of lipid absorption function of a structured lipid medical food (SLMF; Encala®) powder in subjects with PDAC and NET with EPI.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Pancreatic ductal adenocarcinoma or pancreatic neuroendocrine tumor diagnosis and age greater than or equal to 18 years
* Life expectancy of 4 months or greater
* Oral or enteral tube feeding for \> 60% daily calories
* For patients with NET, evidence of GI dysfunction such as \>5% unintentional weight loss, increased number of bowel movements¸change in stool consistency (e.g., soft stool or diarrhea), as documented in the medical record and confirmed by the treating oncologist.
Exclusion Criteria:
* Pregnant or lactating
* Unable to consume food by mouth (oral intake)
* Allergy to soy lecithin product ingredients
* Psychosocial environment for which study participation may be difficult for subject or family, as confirmed by medical team
* Military service members, Reserve Service members, National Guard members, Department of Defense (DoD) civilians, and DoD contractors
* Patients with diminished capacity to consent
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Feasibility of Encala Intervention ( Enrollment Rate )
Timeframe: From enrollment to end of intervention at 8 weeks
2
Change in PROMIS Gastrointestinal Symptom Score
Timeframe: Baseline to Week 8
3
Feasibility of Encala Intervention ( Retention Rate )
Timeframe: Baseline to Week 8
4
Feasibility of Encala Intervention ( Visit Completion)
Timeframe: Baseline to Visit 8
5
Feasibility of Encala Intervention ( Product Adherence )